Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	99661
Country	China

Received	2024-07-27 05:32
Peer-Review Started	2024-07-27 05:32
To Make the First Decision
Return for Revision	2024-09-16 23:40
Revised	2024-09-17 19:22
Second Decision	2024-10-09 02:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-10-09 06:35
Articles in Press	2024-10-09 06:35
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-10-11 06:04
Publish the Manuscript Online	2024-10-25 10:27

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	From biomarker discovery to combined therapies: Advancing hepatocellular carcinoma treatment strategies
Manuscript Source	Invited Manuscript
All Author List	Mo-Wei Kong, Yang Yu, Ying Wan, Yu Gao and Chun-Xiang Zhang
ORCID	Author(s) ORCID Number Mo-Wei Kong http://orcid.org/0000-0002-1214-164X Chun-Xiang Zhang http://orcid.org/0000-0001-8303-6495
Funding Agency and Grant Number	Funding Agency Grant Number TNational Natural Science Foundation of China U23A20398 National Natural Science Foundation of China 82030007 Sichuan Science and Technology Program 2022YFS0578
Corresponding Author	Chun-Xiang Zhang, MD, Professor, Department of Pharmacology and Rush University Cardiovascular Research Center, Rush University Medical Center, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. zhangchx999@163.com
Key Words	Hepatocellular carcinoma; Triple therapy; Transarterial chemoembolization; Protein tyrosine phosphatase non-receptor II
Core Tip	This article review the integration of novel combined therapies and biomarker identification in hepatocellular carcinoma (HCC) management. The studies by Zhang et al and Li et al explore the efficaciousness of a triple therapy involving transarterial chemoembolization, tyrosine kinase inhibitors, and PD-1 inhibitors, and the prognostic value of protein tyrosine phosphatase non-receptor II (PTPN2), respectively. These investigations underscore the significance of PTPN2 as a potential therapeutic target and highlight the promise of synergistic treatment strategies in enhancing HCC patient outcomes.
Publish Date	2024-10-25 10:27
Citation	<p>Kong MW, Yu Y, Wan Y, Gao Y, Zhang CX. From biomarker discovery to combined therapies: Advancing hepatocellular carcinoma treatment strategies. <i>World J Gastrointest Oncol</i> 2024; 16(11): 4518-4521</p>
URL	https://www.wjgnet.com/1948-5204/full/v16/i11/4518.htm
DOI	https://dx.doi.org/10.4251/wjgo.v16.i11.4518

Full Article (PDF)	WJGO-16-4518-with-cover.pdf
Manuscript File	99661_Auto_Edited_074326.docx
Answering Reviewers	99661-answering-reviewers.pdf
Audio Core Tip	99661-audio.wav
Conflict-of-Interest Disclosure Form	99661-conflict-of-interest-statement.pdf
Copyright License Agreement	99661-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	99661-foundation-statement.pdf
Non-Native Speakers of English Editing Certificate	99661-non-native-speakers.pdf
Peer-review Report	99661-peer-reviews.pdf
Scientific Misconduct Check	99661-scientific-misconduct-check.png
Scientific Editor Work List	99661-scientific-editor-work-list.pdf
CrossCheck Report	99661-crosscheck-report.pdf